Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 3, Issue 2, Pages 79-84
http://dx.doi.org/10.1080/13577149977686

Susceptibility of Fibromatosis Cells in Short-Term Culture to Ifosfamide: A Possible Experimental Treatment in Clinically Aggressive Cases

1University of Newcastle Department of Medical Oncology, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6B E, UK
2CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
3Sarcoma Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Deep fibromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the mainstay of treatment, in unremitting and aggressive cases the use of cytotoxic chemotherapy may produce objective tumour responses. Fresh tumour samples from four patients with fibromatosis were investigated as part of a study of drug resistance in soft tissue tumours.

Methods. Following short-term culture of fibromatosis cells in vitro , chemosensitivity to 4-hydroperoxy-ifosfamide, the active form of ifosfamide and doxorubicin was tested. Following 72-h continuous exposure to each drug, surviving cell fraction was assessed using the lactate dehydrogenase assay.

Results. Mean IC50 values for ifosfamide and doxorubicin were 6.2 and 0.35 µmol/l, respectively. In samples of soft tissue sarcoma (STS) from the same study the mean IC50 values for ifosfamide and doxorubicin were 14.8 and 1.69 µmol. The difference in mean ifosfamide IC50 values for fibromatosis and STS samples was statistically significant.

Discussion. We are not aware of any other report suggesting the use of ifosfamide in this condition. These observations suggest that, for patients with inoperable or progressive lesions of fibromatosis causing significant morbidity, it may be valuable to include ifosfamide in experimental treatment regimens.